What is KPV peptide? Research and status in the Philippines

What is KPV?

KPV is a synthetic peptide made of three amino acids: lysine, proline and valine (Lys-Pro-Val). It matches the last three amino acids of alpha-melanocyte-stimulating hormone (alpha-MSH), which is why it is also called alpha-MSH (11-13).

It is investigational. No FDA-approved drug or EU-authorized product contains it, and no published human study was found. The US FDA reviewed two forms, KPV free base and KPV acetate.

How is KPV thought to work?

No one knows exactly how KPV works. The US FDA says "the molecular targets underlying the pharmacological effects of KPV-related BDSs remain unknown."

The ideas below come from lab and animal studies only:

• Not the usual hormone receptors: a 2010 review says KPV "lacks the entire sequence motif required for binding to any of the known MC-Rs" (melanocortin receptors), yet "retains almost all of the anti-inflammatory capacity of the full hormone", without the hormone's tanning action in the studies reviewed. The US FDA agrees that "several lines of evidence suggest that MC receptors are unlikely to be the molecular targets".
• Inflammation signals: researchers have proposed that KPV blocks NF-kappaB activation and the effects of inflammatory messengers such as interleukin 1-beta.
• Gut transporter: researchers have proposed that a transporter called PepT1 carries KPV into intestinal and immune cells.
• Skin: in a lab study using human cadaver skin, the US FDA notes that KPV "does not permeate well through skin", which could limit both how much reaches the body and its usefulness as a skin treatment.

What do animal and lab studies show?

All published KPV research is preclinical: studies in cells and animals, mostly mice. These results do not show that KPV works, or is free of harm, in people.

What human evidence exists?

None. The US FDA's 2026 review found that "No published studies were found in which non-compounded or compounded drug products containing KPV (free base) or KPV acetate were used in humans."

• The nomination: the request to allow KPV in US compounding cited nine references, and "none were studies of KPV administered in humans."
• How the body handles it: the FDA found no human pharmacokinetic studies (how the body absorbs, spreads and clears a drug).
• Trials: a search of ClinicalTrials.gov on October 7, 2026 found no registered study of KPV.

What did the US FDA's review find?

In 2026 the US FDA reviewed KPV and proposed keeping it off the list of substances US pharmacies may use for compounding.

The FDA's proposal: "we propose not adding KPV (free base) or KPV acetate to the 503A Bulks List." It said the briefing is not its final determination. The committee's reported vote went the other way. DLA Piper notes that "committee votes are non-binding recommendations, formal rulemaking is required before any substance is added to the list, and FDA is not obligated to follow the AdComm's recommendations." The FDA's findings:

• No human studies: no published human studies of any KPV product.
• No toxicity studies: no acute toxicity, repeat-dose toxicity, genotoxicity, reproductive toxicity or carcinogenicity studies were submitted or found.
• Not well characterized: the FDA found both forms "not well-characterized", because naming is inconsistent with recognized standards and quality controls for impurities, aggregates (clumped peptide) and microbial contamination were not found.
• Thin certificates of analysis: most certificates of analysis the FDA found for KPV listed only a purity result. The nominator's certificate named one form of KPV in its title and a different form in its molecular formula.
• No official standards: there is no USP or NF monograph for KPV, and neither form is a component of an FDA-approved drug. The European and Japanese Pharmacopoeias have no KPV monograph, and the European Medicines Agency "did not list any products containing KPV (free base) or KPV acetate that are authorized for use."

Registered US outsourcing facilities reported no KPV products from 2017 to June 2025.

Risks and unknowns

The risks of KPV in people are unknown, because no human study of it was found.

• No human data: the US FDA says "FDA has not identified any human exposure data on drug products containing KPV administered via any route of administration. FDA lacks important information regarding any safety issues raised by KPV, including whether it would cause harm if administered to humans."
• Immune reactions: the FDA is "particularly concerned about the lack of any human data on drug products containing these substances administered via any route of administration, including lack of information to assess immunogenicity or aggregation". It explains that immune reactions to peptides can range from no symptoms to "life-threatening and catastrophic reactions".
• No toxicity testing: no standard animal toxicity studies of KPV were found by the FDA.
• No reports is not the same as no risk: a search of the FDA's adverse event database through December 3, 2025 found no reports for KPV. The FDA notes that reporting is voluntary and that 503A compounders generally do not report adverse events, so this does not show that KPV is free of risk.
• Unregistered products: FDA Philippines says the unregistered injectable KPV product it warned about gives the public "no assurance as to its quality, safety and efficacy", and that using it "may expose them to potential health risks, including possible injury or harm."

No regulator or peer-reviewed lab analysis of the identity or purity of KPV products was found.

Status in the Philippines

No FDA Philippines registration for KPV was found, and FDA Philippines has warned the public against one unregistered injectable KPV product. No compound-level FDA Philippines statement on KPV was found.

What the FDA Philippines verification portal showed on October 7, 2026 (search results, not an official ruling):

Other points:

• Injectable product warning: in Advisory No. 2026-1013, FDA Philippines found that an injectable KPV product had no Certificate of Product Registration and warned the public not to purchase or use it.
• Prescription status: no Philippine source (FDA Philippines, DOH, PhilHealth or PRC) on prescription status, compounding or enforcement for KPV beyond the advisory was found.
• Check a product yourself: FDA Philippines advises the public to check whether products are registered using its verification portal at verification.fda.gov.ph.

For how Philippine rules treat peptides in general, see are peptides legal in the Philippines.

FDA advisory history

FDA Philippines has issued one advisory naming KPV.

A Filipino version was issued as No. 2026-1013-A. On October 7, 2026, searches of the FDA Philippines website for "lysine-proline-valine" and "alpha-MSH" returned nothing.

A missing advisory does not mean a product is registered or approved. For another peptide the US FDA reviewed for compounding in 2026, see BPC-157.

What to ask a doctor

If you are thinking about KPV, or have already used it, a licensed doctor can help. Questions you could bring:

• What approved treatments exist for my gut, skin or inflammatory condition, and what does the evidence show for them?
• What should I watch for if I have already injected an unregistered peptide product?
• If I compete in sport, how should I check whether a substance is allowed?
• How can I check whether a product is registered with FDA Philippines?